- In early April 2026, Cardinal Health announced a major expansion of Actinium-225 production at its Center for Theranostics Advancement in Indianapolis, adding a high-capacity line to its Drug Master File to boost cGMP-compliant supply for investigational and future commercial targeted alpha therapies.
- This enlarged Actinium-225 footprint, already supporting more than 15 clinical trials worldwide, deepens Cardinal Health’s role as a key radiopharmaceutical partner for oncology drug developers and theranostics programs.
- We’ll now examine how Cardinal Health’s expanded Actinium-225 capacity at its theranostics center could reshape the company’s broader investment narrative.
Uncover the next big thing with 33 elite penny stocks that balance risk and reward.
Cardinal Health Investment Narrative Recap
To own Cardinal Health, you need to believe in its core as a large-scale distributor while seeing upside in higher value services like radiopharmaceuticals. The Actinium-225 expansion reinforces that specialty push but does not materially change near term earnings catalysts or the key risks around regulation, reimbursement pressure, and major customer contract exposure.
The recent continuation of share repurchases, with US$1,483.96 million spent on buybacks through December 2025, sits alongside this Ac-225 capacity buildout and shows the company balancing capital return with growth investments. How that balance holds up if tariff and reimbursement pressures intensify is an open question for investors watching upcoming results.
Yet despite these strengths, investors should still be aware of how renewed government pricing scrutiny and reimbursement changes could...
Read the full narrative on Cardinal Health (it's free!)
Cardinal Health's narrative projects $317.2 billion revenue and $2.6 billion earnings by 2029. This requires 9.0% yearly revenue growth and about a $0.9 billion earnings increase from $1.7 billion today.
Uncover how Cardinal Health's forecasts yield a $249.60 fair value, a 17% upside to its current price.
Exploring Other Perspectives
Four members of the Simply Wall St Community currently place Cardinal Health’s fair value between US$168.25 and US$495.89, highlighting very different expectations. You can weigh those views against the potential impact of expanding Ac-225 production on future earnings resilience.
Explore 4 other fair value estimates on Cardinal Health - why the stock might be worth 21% less than the current price!
The Verdict Is Yours
Don't just follow the ticker - dig into the data and build a conviction that's truly your own.
- A great starting point for your Cardinal Health research is our analysis highlighting 3 key rewards and 2 important warning signs that could impact your investment decision.
- Our free Cardinal Health research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Cardinal Health's overall financial health at a glance.
Contemplating Other Strategies?
Our top stock finds are flying under the radar-for now. Get in early:
- Rare earth metals are the new gold rush. Find out which 27 stocks are leading the charge.
- Explore 23 top quantum computing companies leading the revolution in next-gen technology and shaping the future with breakthroughs in quantum algorithms, superconducting qubits, and cutting-edge research.
- The future of work is here. Discover the 34 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com